BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Research

Neurizon Completes Rapid Phase II/III NUZ-001 Enrolment for ALS with Results Expected in Q2 2027

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY AL...

July 20, 2026 | News

Merck Invests €25M to Expand BioReliance Testing Capabilities in Europe

• New 2,000-square-meter facility expands Merck’s global testing network with commercial drug substance and drug product release testing a...

July 17, 2026 | News

Australia Builds a New Radiopharmaceutical Gateway from Research to Patient Care

First-of-its-kind facility in Australia where radiopharmaceuticals are developed, manufactured and administered to patients under one roof. Patient care...

July 17, 2026 | News

BioArctic and Eisai Secure FDA Approval for At-Home Leqembi Injection to Treat Early Alzheimer's Disease

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced that the US Food and Drug Administration (FDA) has approved a supplement...

July 15, 2026 | News

China Grants Priority Review to Leads Biolabs' Opamtistomig for Advanced Neuroendocrine Cancer

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced that the biologics license application (BLA) for Op...

July 13, 2026 | News

ACHP Launches Patient Advisory Council to Put Chronic Disease Voices at the Heart of Research

The Alliance of Community Health Plans (ACHP) is amplifying patients' voices on chronic disease research via its newly launched Patient Advisory Council. T...

July 13, 2026 | News

Lynk Pharmaceuticals Doses First Patient in Phase II Trial of Novel Vitiligo Therapy

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...

July 10, 2026 | News

Healome Therapeutics Raises £2 Million Seed Funding to Advance Eye-Drop Platform for Ocular Surface Diseases

Healome Therapeutics ("Healome"), a University of Birmingham spinout developing a proprietary eye-drop matrix technology for ocular surface diseases, has c...

July 09, 2026 | News

LG Chem and OTR Therapeutics Partner to Advance China-Sourced Oncology Assets Globally

OTR Therapeutics, a clinical-stage biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, today an...

July 09, 2026 | News

Singapore Updates Wegovy Label to Include Higher-Dose Semaglutide Data Showing Up to 25% Weight Loss

Up to one in three participants on semaglutide 7.2 mg achieved at least 25% weight loss over 72 weeks Mean weight loss with semaglutide 7.2 mg reached 2...

July 09, 2026 | News

Europe Approves TEPKINLY Combination as First Bispecific-Based Second-Line Therapy for Follicular Lymphoma

TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Euro...

July 08, 2026 | News

Arima Genomics Partners with Active Motif to Expand Global Access to Hi-C Research Portfolio

Agreement Part of Arima’s Long-Term Strategy to Focus on Core Diagnostic Platform and Tests Arima Genomics, Inc., a cancer diagnostics com...

July 07, 2026 | News

Immunomic Therapeutics Doses First Patient in Phase 1 Trial of saRNA Allergy Vaccine in Japan

First patient dosed less than one month after PMDA clearance, demonstrating rapid clinical execution Next-generation UNITE® saRNA-based immunother...

July 07, 2026 | News

Ever Supreme Advances Off-the-Shelf CAR-T Therapy CAR001 to Phase IIa After Positive Phase I Safety Review

Ever Supreme Bio Technology Co., Ltd. (TWSE: 6712) announced on June 28 that CAR001, its proprietarily developed, allogeneic, "off-the-shelf" CAR...

July 01, 2026 | News

Stay Connected